Evidence map›Paper›PMID 32714984›Full record

ArticleBioMed research international2020

Prognostic Value of the LATITUDE and CHAARTED Risk Criteria for Predicting the Survival of Men with Bone Metastatic Hormone-Naïve Prostate Cancer Treated with Combined Androgen Blockade Therapy: Real-World Data from a Japanese Multi-Institutional Study.

Takashi Kawahara, Shuko Yoneyama, Yoshio Ohno, Junpei Iizuka, Yasunobu Hashimoto, Hideyasu Tsumura, Ken-Ichi Tabata, Yoshihiro Nakagami, Kazunari Tanabe, Masatsugu Iwamura and 2 more

Open access · hybridAbstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in BioMed research international, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed, 1 pooled it
1.6field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 1 synthesis or guideline pooled it, 23 citations in OpenAlex.

  1. Radiotherapy for hormone-sensitive prostate cancer with synchronous low burden of distant metastases.Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2022
    Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 5 institutions in 1 country.

Takashi KawaharaDepartments of Urology and Renal Transplantation, Yokohama City University Medical Center, Yokohama, Japan.ORCID https://orcid.org/0000-0002-7049-3379
Shuko YoneyamaDepartments of Urology and Renal Transplantation, Yokohama City University Medical Center, Yokohama, Japan.
Yoshio OhnoDepartment of Urology, Tokyo Medical University, Tokyo, Japan.
Junpei IizukaDepartment of Urology, Tokyo Women's Medical University, Japan.
Yasunobu HashimotoDepartment of Urology, Saiseikai Kawaguchi General Hospital, Saitama, Japan.
Hideyasu TsumuraDepartment of Urology, Kitasato University School of Medicine, Sagamihara, Japan.
Ken-Ichi TabataDepartment of Urology, Kitasato University School of Medicine, Sagamihara, Japan.
Yoshihiro NakagamiDepartment of Urology, Tokyo Medical University, Tokyo, Japan.
Kazunari TanabeDepartment of Urology, Tokyo Women's Medical University, Japan.
Masatsugu IwamuraDepartment of Urology, Kitasato University School of Medicine, Sagamihara, Japan.
Hiroji UemuraDepartments of Urology and Renal Transplantation, Yokohama City University Medical Center, Yokohama, Japan.ORCID https://orcid.org/0000-0003-3775-2671
Yasuhide MiyoshiDepartments of Urology and Renal Transplantation, Yokohama City University Medical Center, Yokohama, Japan.ORCID https://orcid.org/0000-0001-8857-9798
Yokohama City University Medical Center · JPKitasato University · JPTokyo Medical University · JPTokyo Women's Medical University · JPSaiseikai Fukuoka General Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe CHAARTED and LATITUDE trials demonstrated a prolonged overall survival (OS) for metastatic hormone-naïve prostate cancer (mHNPC) patients who receive up-front docetaxel or abiraterone acetate. These studies used their own risk criteria: CHAARTED trial defines high- and low-volume diseases and LATITUDE trial targeting a high-risk disease. The present study explored whether or not the CHAARTED and LATITUDE criteria were useful for predicting the outcome in Japanese bone mHNPC patients, including elderly patients (≥70 years).

methodsA total of 532 mHNPC patients diagnosed from 2004 to 2014 in multithird referral cancer centers were enrolled in this study. All patients had bone metastasis and received combined androgen blockade treatment as an initial hormonal therapy.

resultsThe number of patients with CHAARTED low-volume and high-volume diseases was 178 (33.5%) and 354 (66.5%), respectively. On the contrary, the number of patients with LATITUDE low-risk and high-risk diseases was 157 (29.5%) and 375 (70.5%), respectively. A total of 307 (57.7%) patients were defined as having both CHAARTED high-volume and LATITUDE high-risk disease. The median castration-resistant prostate cancer- (CRPC-) free survival was 12.5 months for the CHAARTED high volume, 56.9 months for the CHAARTED low volume, 13.6 months for the LATITUDE high risk, and 37.3 months for the LATITUDE low risk, respectively. The OS was 50.1 months in patients with CHAARTED high-volume disease, 95.1 months in patients with CHAARTED low-volume disease, 54.0 months in patients with LATITUDE high-risk disease, and 92.7 months in patients with LATITUDE low-risk disease, respectively. This trend was also observed in elderly (≥70 years old) patients.

conclusionsThe patients with CHAARTED high-volume disease or LATITUDE high-risk disease showed a shorter CRPC-free survival and a shorter OS than those in the CHAARTED low-volume disease group or in the LATITUDE low-risk group among Asian Japanese bone metastatic HNPC patients.

Indexed as

AdultAgedAged, 80 and overAge DistributionAndrogen AntagonistsBone NeoplasmsHumansMaleMiddle AgedMultivariate AnalysisPrognosisProstatic NeoplasmsProstatic Neoplasms, Castration-ResistantRisk FactorsSurvival AnalysisAndrogen Antagonists

Identifiers

PMID32714984
PMCPMC7352129
OpenAlexW3038495104

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.